MDRAB strains were negative for qnrA, qnrB and qnrS and other studies have shown that qnr in A. baumannii is not widespread. 4 Four of the eight qnr genes were found in ciprofloxacin-resistant isolates and three in isolates with intermediate susceptibility. C. freundii harboured qnrB8 and was ciprofloxacin-susceptible. Six of the eight (75%) qnr-positive isolates were ESBL-producing strains representing 11% of all the ESBL-positive isolates (n¼53). x 2 analysis showed that qnr was associated with ESBL-producing strains (P,0.01). Quinolone conjugation studies have revealed that the presence of qnr does not confer high-level resistance, although it has been shown that the qnr gene is able to co-localize with other antibiotic resistance determinants on a plasmid. 5 This implies that although they may not be the cause of resistance, qnr genes are associated with isolates that have reduced susceptibility.
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Hector Rodriguez-Villalobos*, Alina Cardentey-Reyes, Christine Thiroux, Claire Nonhoff and Marc J. Struelens Microbiology Department, Université Libre de Bruxelles-Hôpital Erasme, Bruxelles, Belgium Keywords: Vitek 2, Etest, disc diffusion *Corresponding author. Tel: þ32-2-555-45-18; Fax: þ32-2-555-31-10; E-mail: hrodrigu@ulb.ac.be Sir, Temocillin is a semi-synthetic 6-a-methoxylpenicillin derivate of ticarcillin. Its stability to bacterial b-lactamases was confirmed against the majority of extended-spectrum b-lactamases (ESBLs) including CTX-M enzymes. 1, 2 In vitro susceptibility testing for temocillin can be performed by broth dilution, disc diffusion method or Etest (AB Biodisk, Solna, Sweden). The Vitek 2 system (bioMérieux, France) has developed new Gram-negative antibiotic susceptibility testing cards that include temocillin. Limited data have been published concerning the accuracy of these different susceptibility test methods for this antibiotic. We compare the accuracy of the Vitek 2 system, Etest and two disc diffusion methods (30 mg paper discs from Becton Dickinson, USA and Neo-Sensitabs from Rosco, Denmark) to determine the susceptibility of Escherichia coli strains to temocillin. Strains were recovered from urine specimens (57%), screening rectal swabs (25%), respiratory samples (7%), wound swabs (4%) and other samples (7%). Isolates included ESBL-producing strains (n ¼ 88) harbouring CTX-M enzymes in 70 isolates (CTX-M-2, CTX-M-9, CTX-M-15), TEM (TEM-24, TEM-30, TEM-52) in 12 isolates and SHV-12 enzymes in 6 isolates. Non-ESBL isolates (n ¼ 68) included 15 AmpC-hyperproducing strains, 25 with wild-type phenotype and 28 with other antibiotic resistance mechanisms.
Production of ESBL was detected by the combined disc method (Bio-Rad, France). The genotypic characterization of the ESBLs was performed by PCR to detect bla TEM , bla SHV and bla CTX-M genes in all isolates, PCR for CTX-M groups in CTX-M-producing strains and DNA sequencing (n ¼ 25) as described previously.
Strains were tested by disc diffusion (paper discs and Neo-Sensitabs) and MIC determination by Etest (AB Biodisk) methods and were inoculated at the same time in AST-N045 and AST-N046 cards for Vitek 2. The agar dilution method was performed according to the CLSI recommendations, as the gold standard method. 3 Susceptibility to temocillin was determined according to breakpoints provided by Fuchs et al. 4 (susceptible, 16 mg/L; resistant, !32 mg/L) and to BSAC breakpoints for urinary tract or systemic samples (MIC 32 mg/L and MIC 8 mg/L, respectively). 5 Interpretation criteria for temocillin paper discs were those published by Fuchs et al. 4 (Table 1) . Errors were observed with seven isolates showing borderline temocillin MICs of 16 mg/L. Disc diffusion with Neo-Sensitabs showed fewer discrepancies than with paper discs. The majority of discrepancies with the disc diffusion method were observed among strains showing borderline temocillin MICs of 16 or 32 mg/L. No discrepancies were observed for strains showing MICs ,4 mg/L. Neo-Sensitabs showed better discrimination between temocillin-susceptible and -resistant strains than paper discs. All discrepancies with the disc diffusion method were observed in multiresistant strains.
In this study, we focused on E. coli because of the clinical value of temocillin for the therapy of complicated community-acquired urinary tract infection, which is caused by this pathogen in the vast majority of cases. A recent study of temocillin susceptibility of Enterobacteriaceae showed a high false susceptibility rate by using the paper disc method, particularly in Serratia spp., and a 2% false resistance rate in E. coli by using the systemic BSAC breakpoint. 5 In our study, when this breakpoint was used, the percentages of total errors were 15% and 14% (including 2% to 4% very major errors) with Etest and Vitek 2, respectively. By using the urine BSAC breakpoint, an overall agreement of 94% was observed between the gold standard and Vitek 2 results. The results of 10 strains showing MICs of 32 mg/L by agar dilution and MICs of !32 mg/L by Vitek 2 were not interpretable. Indeed, these susceptible strains will be systematically categorized as resistant by the Vitek 2 expert system. Temocillin breakpoints remain controversial, but a recent study suggests that 8 mg/L seems to be more appropriate on the basis of inter-individual variabilities in serum drug levels. 6 Our findings confirm that both Etest and the Vitek 2 system are accurate methods to determine MICs of temocillin for E. coli, including ESBL-and AmpC-producing strains by using Fuchs et al.'s 4 breakpoint values. New calibration and/or re-design of the AST-N045 and AST-N046 Vitek cards is warranted for use with the BSAC breakpoints. In our study, Neo-Sensitabs discriminated better between susceptible and resistant strains than paper discs.
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